Formulation And Evaluation Of Transdermal Drug Delivery System For Safe And Effective Treatment Of Airways Disorders

Abstract

Airway disorders are the obstructions in the oxygen tubes of the lungs which causes newlinedisorders such as nasal congestion, asthma, sinus, cystic fibrosis and rhinitis. To overcome the problem of nasal congestion various nasal decongestants are available in market. newlineXylometazoline hydrochloride (XYL) is a nasal decongestant which causes systemic newlinevasoconstriction by directly affecting the adrenergic alpha-agonist. The availability of newlineXYL nasal spray causes side effects such as temporary burning, stinging, rebound effect, newlinedryness in the nose and repeated frequency of drug administration. It also causes rapid newlinedrug clearance (mucociliary clearance) from the nasal cavity due to low residence time. newlineOur research is to fabricate the transdermal patch loaded with XYL chitosan nanoparticles newline(XYL-CH-NP) for sustained drug release into the nasal cavity. These patches will newlinefacilitate drug absorption through the mucosa lining and improve the drug systemic newlineavailability. XYL-CH-NP were prepared using ionotropic gelation method. They were newlineoptimized and validated by Box-Behnken Design. Further, they were characterised for size,morphology and evaluated for its release and permeability studies. XYL-CH-NP showed a newlineparticle size of 172+0.4 nm and a PDI of 0.27. The obtained charged nanoparticles showed newlineencapsulation efficiency of 90.5%. Transmission Electron Microscopy (TEM) and newlineScanning Electron Microscopy (SEM) studies showed nanoparticles have small size and newlinesmooth morphology and an in-vitro drug release of 73.66%, following Peppas-korsemeyer newlinerelease model 96.53% of the drug was permeated through the nasal mucosa of the goat in a newlinetime period of 8 h. Release and permeation resultsshows the capability of the nanoparticles newlineto retain large amount of XYL-NP inside the mucosa.The next step was to load the XYLCH- newlineNP into a transdermal patch for prolonged and sustained medication release into the newlinenasal cavity for the treatment of nasal congestion. Drug release from the transdermal patchwas found to be 87.2 % which fitted into the Higuchi mode